Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 34.95 as of 2026-09-17T20:25:49.983Z.
Consensus retrieved: 2026-09-13T23:22:10.515Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-17T20:25:49.983Z.
Quote observation: 2026-09-17T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9b48f62db508c30c3900ea5253145910cc956ecc0d76dd275063bdd80f802346
Forward PE Ratio (34.95) = Dated Quote Price ($615.18) / Consensus Forward EPS ($17.60)
FORWARD PE RATIO
34.95
SECTOR MEDIAN · HEALTHCARE
18.94
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+84.53%
vs the sector median at left
Medpace Holdings, Inc.
Market Cap
$17.17B
Forward PE Ratio
34.95
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $17.17B | 34.95 |
| Revvity, Inc. (RVTY)vs › | $16.37B | 27.40 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.23B | 11.05 |
| Solventum Corporation (SOLV)vs › | $15.16B | 12.23 |
| Exelixis, Inc. (EXEL)vs › | $14.70B | 16.65 |
| Viatris Inc. (VTRS)vs › | $19.95B | 6.85 |
| Tempus AI, Inc. (TEM)vs › | $14.08B | N/A |
| STERIS plc (STE)vs › | $20.28B | 18.56 |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.57B | 24.88 |
| United Therapeutics Corporation (UTHR)vs › | $21.11B | 19.02 |
Trailing P/E
36.0
reported TTM EPS
Forward P/E
35.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $17.60 implies +3.1% EPS growth vs the reported trailing $17.07.
At the dated quote price of $615.18, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $17.60 | $17.50 – $17.68 | 9 | 34.9x |
| 2027-12-31 | $19.35 | $18.87 – $19.78 | 9 | 31.8x |
| 2028-12-31 | $21.50 | $20.47 – $22.64 | 9 | 28.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
